Search fresh public links, source activity, and post angles for Best In Biotech.
Fresh curated links around Best in Biotech are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
The companies Earendil Labs, Teva Pharmaceuticals, and Solid Biosciences bagged the biggest biotech funding rounds overall in March 2026. The post The biggest biotech funding round...
Novo Nordisk and Biogen are underpriced and stand to gain from new indications for their blockbuster therapies.
Hemab Therapeutics and Seaport Therapeutics are the newest biotech companies to join the public markets, each with an upsized IPO. According to IPO research firm Renaissance Capita...
Discover what were the top biotech deals that were signed in March 2026. From small molecules to antibodies, M&A activity was high. The post Top biotech deals in March 2026 ap...
Issued on behalf of Avaí Bio, Inc. VANCOUVER, British Columbia, April 08, 2026 (GLOBE NEWSWIRE) — USANewsGroup.com News Commentary — Biotechs that went public in Q1 2026 raised a m...
The biggest biotech acquisition deal so far in 2026 was announced in April. Deals were sealed over ADCs, small molecules, AI platforms, and T-cell engagers. The post Top biotech...
Kailera Therapeutics, Nektar Therapeutics, and Hemab Therapeutics bagged the biggest biotech funding rounds overall in April 2026. The post The biggest biotech funding rounds in Ap...
Investors are still waiting to see whether Bristol Myers and Regeneron’s pipelines will deliver, while Biogen was lifted by better-than-expected results for newer drugs like Leqemb...
It will be a turbulent ride, but patient investors might come out of it much richer.
Structure Therapeutics advances oral therapies for chronic diseases, with a pipeline focused on metabolic and pulmonary conditions.
Structure Therapeutics advances oral therapies for chronic diseases, with a pipeline focused on metabolic and pulmonary conditions.
The pharmaceutical industry is entering a new era of hyper-growth, specifically within subsectors powered by next-generation biological and genetic engineering. These fields are cu...
It's time to kick off our annual hunt for the latest crop of trailblazing biotechs that we sense are going to shape the industry of the future.
Inhibrx, the subject of recent buyout rumors, showed its drug might enhance the effects of Keytruda. Elsewhere, Capricor sued its cell therapy partner and Argenx got a revenue boos...
The past year marked a proverbial inflection point for organoid models designed to uncover biological insights previously unattainable through traditional cell culture experiments...
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.